Clinical trials Below are current clinical trials.117 studies in Neurology (open studies only). Filter this list of studies by location, status and more. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Rochester, Minn. The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts. A Study of Molecular Anatomic Imaging Analysis of Tau, the Primary Pathological Protein in Progressive Supranuclear Palsy Rochester, Minn. The purpose of this study is to learn more about the distribution of the pathological protein tau in the living brains of patients with Progressive Supranuclear Palsy (PSP). A Study of Pyridostigmine in Postural Tachycardia Syndrome Rochester, Minn. This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure. A Study of Nervous System Involvement of Coccidioidomycosis at Mayo Clinic Hospital in Arizona Scottsdale/Phoenix, Ariz. The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis. A Study to Evaluate a Color Test for Patients with Optic Nerve Diseases Rochester, Minn. The purpose of this study is to evaluate the clinical utility of a quantitative test to measure how color saturation appears in patients with diseases of the optive nerve. Immune Phenotyping in Amyotrophic Lateral Sclerosis Rochester, Minn. The goals of this study are to identify biomarkers that allow improved staging or prognosis of the disease, and through the discovery of previously unrecognized immune abnormalities in ALS we aim to eventually identify immune therapies that may provide benefit in ALS. A Study of Factors That Predispose, Promote, and Perpetuate Post-Traumatic Dizziness Rochester, Minn. The purpose of this study is to investigate whether recent, groundbreaking discoveries about key pathophysiologic processes that drive chronic dizziness in patients without traumatic brain injury (TBI9,10) are applicable to patients with post-mTBI vestibular disability. We expect the results of this project to have practical clinical and research applications, providing novel data for two future steps: A Study to Evaluate Quantitative Phenotypes of Movement Disorders Jacksonville, Fla. The purpose of this study is to determine if adaptive rhythmic auditory stimulation (ARAS) is a safe means of improving gait; i.e., fewer falls, abrupt accelerations/decelerations in patients with movement disorders. Furthermore, we aim to provide patients with a safe environment in which they can safely navigate through an enjoyable experience (guided art tour) that provides exercise, social engagement, and exposure to art. A Study to Evaluate Pluripotent Stem Cell Models for Spinal Muscular Atrophy (SMA) Patients Rochester, Minn., La Crosse, Wis., Jacksonville, Fla. The purpose of this study is to perform RNA sequencing on induced pluripotent stem cells (iPSC). By comparing the gene expression of motor neurons derived from iPSC cells of phenotypically discordant Spinal Muscular Atrophy (SMA) sibling pairs and individual cases of SMA, we hope to identify potential protective gene modifiers of SMA. Identifying protective gene modifiers will increase our understanding of the molecular pathogenesis of SMA. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC). Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page Request an appointment Expertise & rankingsResearch June 19, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, and Mayo Clinic in Jacksonville, Florida, have been ranked among the best Neurology & Neurosurgery hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor NeurologyDepartmenthomeSectionsOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20117054 Medical Departments & Centers Neurology